Efficacy of eribulin in breast cancer: a short report on the emerging new data by Eslamian, G. et al.
© 2017 Eslamian et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
OncoTargets and Therapy 2017:10 773–779
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
773
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OTT.S102638
Efficacy of eribulin in breast cancer: a short 
report on the emerging new data
Gelareh eslamian
Caroline wilson
Robin J Young
Academic Unit of Clinical Oncology, 
weston Park Hospital, Sheffield, UK
Abstract: Eribulin is a novel microtubule-targeting agent that is approved for the treatment 
of patients with locally advanced or metastatic breast cancer who have previously received 
treatment with an anthracycline and a taxane in either the adjuvant or metastatic setting. 
Eribulin induces mitotic catastrophe leading to cell death but has other important antitumor 
effects, including reversal of epithelial–mesenchymal transition and remodeling of the tumor 
vasculature. Eribulin was licensed for the treatment of advanced breast cancer based on results 
from two large randomized Phase III clinical trials. Current clinical trials of eribulin for breast 
cancer are evaluating response to treatment earlier in the patient pathway and in combination 
with other therapeutic agents. This review provides a short overview of emerging new data on 
the mode of action of eribulin in breast cancer.
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Introduction
Microtubules are a key component of the cytoskeleton. They are highly dynamic 
structures that are formed from polymers of α and β tubulin heterodimers, aligned 
into hollow filaments. They play an important role in a variety of cellular processes, 
including mitosis. Microtubule-targeting agents (MTAs) have an established role in the 
treatment of various hematopoietic and solid tumors, including breast cancer. MTAs 
are classified into either microtubule-stabilizing agents (eg, the taxanes paclitaxel and 
docetaxel) or microtubule-destabilizing agents (eg, the vinca alkaloids vincristine 
and vinblastine, and the halichondrin analog eribulin). Both microtubule stabiliz-
ers and microtubule destabilizers suppress spindle dynamics during mitosis, which 
leads to mitotic catastrophe and cell death.1 Eribulin (HALAVEN) was licensed for 
the treatment of locally advanced or metastatic breast cancer following the pivotal 
Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389 
(EMBRACE) study, an international randomized Phase III clinical trial of eribulin 
vs treatment of physician’s choice in 762 patients with locally recurrent or metastatic 
breast cancer previously treated with at least two chemotherapy regimens, including 
an anthracycline and a taxane.2 Here, we review the clinical data supporting the use of 
eribulin for the treatment of metastatic breast cancer and emerging new data around 
its mode of action.
Pharmacology
The macrocyclic polyether halichondrin B was isolated from the sea sponge 
Halichondria okadai in 1986. This compound was found to have promising activity 
in both in vitro and in vivo tumor assays; however, further drug development was 
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limited by the low yields available from natural sources. Fol-
lowing extensive testing of hundreds of simplified synthetic 
analogs designed around the active C1–C38 macrocyclic 
lactone moiety, E7389 (eribulin) was selected for clinical 
development.3
Mechanism of action
Eribulin binds to β tubulin at the microtubule plus end, 
where the β tubulin subunit is exposed, to sterically inhibit 
the polymerization of further tubulin heterodimers. Eribulin 
thus limits microtubule growth but has very little effect on 
microtubule shortening.4,5 Microtubules are essential for the 
correct alignment and separation of sister chromatids during 
the metaphase–anaphase stages of mitosis. The inhibition of 
microtubule growth by eribulin stalls spindle activity during 
mitosis, which signals mitotic catastrophe through mitotic 
checkpoints, and leads to cell death.6,7 In contrast to many 
other MTAs, eribulin exposure is associated with irreversible 
mitotic blockade, despite drug washout. This property may be 
relevant clinically, where treatment schedules are typically 
associated with transient drug exposure.8 Interestingly, the 
efficacy of eribulin correlates inversely with the expression 
of isoform III of the β tubulin subunit.9 This isoform is highly 
expressed in neurons and may partly account for the relatively 
low neuropathy reported by patients treated with eribulin.
Consistent with the role of microtubules in broader cel-
lular functions, exposure to MTAs is associated with off-
target nonmitotic effects, which are likely to contribute to 
their clinical efficacy. A recent in vitro study demonstrated 
reduced intracellular trafficking of DNA repair proteins from 
the cytoplasm to the nucleus in the presence of noncytotoxic 
drug concentrations of paclitaxel and vincristine,10 supporting 
the use of MTAs in combination with DNA-damaging agents, 
including radiotherapy. A similar influence on intracellular 
trafficking may be predicted with eribulin, although a study 
exploring the pathogenesis of MTA-induced peripheral neu-
ropathy reported differences between MTA agents in axonal 
transport along neuronal microtubules; the microtubule-
stabilizing agents paclitaxel and ixabepilone inhibited 
anterograde but not retrograde axonal transport, while the 
microtubule-destabilizing agents eribulin and vincristine had 
effects on axonal transport only at significantly higher drug 
concentrations.11 Another in vitro study demonstrated that 
eribulin interfered with the interaction between microtubule 
plus ends and microtubule tip-associated proteins, which 
are required for chemotaxis, such as the colonic and hepatic 
tumor overexpressed gene protein (ch-TOG), leading to 
decreased breast cancer cell migration.12
Epithelial–mesenchymal transition (EMT) is a process 
crucial to tumor invasion and metastasis and also contributes 
to chemotherapy resistance. Treatment of triple-negative 
breast cancer (TNBC) cells with eribulin reduced cell expres-
sion of mesenchymal markers and increased the expression of 
epithelial markers, both in vitro and in vivo. This was associ-
ated with decreased breast cancer cell migration and invasion 
and reduced metastasis formation in vivo.13 Furthermore, 
exposure of TNBC cells to 5-fluorouracil (5-FU) caused a 
shift from an epithelial to a mesenchymal phenotype and 
induced resistance to 5-FU. Eribulin reversed 5-FU-induced 
EMT transition and sensitized TNBC cells to 5-FU.14
Other preclinical studies have confirmed that eribulin 
treatment is associated with decreased EMT-related gene 
expression and also decreased angiogenesis-related gene 
expression, including vascular endothelial growth factor 
(VEGF) and VEGF receptors;15 the antiangiogenic response 
to eribulin altered the tumor vasculature morphology, 
improved the tumor perfusion, and enhanced the activity 
of subsequently administered chemotherapy. A recent 
interesting clinical study compared differences in breast 
cancer oxygenation between treatment with eribulin and 
bevacizumab;16 this small study of 29 patients reported 
that bevacizumab treatment was associated with increased 
tumor hypoxia, while eribulin treatment was associated with 
improved tumor oxygenation, despite similar inhibition of 
circulating VEGF.
To date, resistance mechanisms to eribulin have been 
relatively understudied. However, it was recently reported 
that breast cancer cell line expression of the ATP-binding 
cassette (ABC) efflux pumps, specifically ABCB1 (also 
known as P-glycoprotein/MDR1) and ABCC11, which 
confer cross-resistance to various chemotherapies, was also 
associated with eribulin resistance in vitro.17
Pharmacokinetics
Eribulin forms a clear colorless aqueous solution for injection. 
In Europe, the recommended dose schedule is 1.23 mg/m2, 
days 1 and 8 of a 21-day cycle, which refers to the base 
of the active substance (eribulin). In the USA, the recom-
mended dose is 1.4 mg/m2, which refers to the salt (eribulin 
mesylate). After intravenous infusion, eribulin has a rapid 
distribution, followed by triexponential elimination, with a 
prolonged terminal half-life of 40 hours but no evidence of 
dose accumulation.18 Cytochrome P450 3A4 has a very minor 
role in the metabolism of eribulin, and it is predominately 
eliminated unchanged by biliary excretion. Dose reductions 
are therefore required in the presence of hepatic impairment19 
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and can be guided by the Child-Pugh score. Less than 10% of 
eribulin is eliminated by renal excretion; however, decreased 
clearance and increased exposure have been reported in 
moderate and severe renal impairment, and dose reduction 
is suggested if the creatinine clearance is ,50 mL/min.20 
Eribulin causes embryo–fetal toxicity and teratogenicity in 
pregnant rats, and with no clinical studies of its safety in 
pregnant women, its use is not recommended.
Eribulin in clinical practice
Eribulin in advanced breast cancer
Eribulin is approved for the treatment of locally advanced 
or metastatic breast cancer in patients who have progressed 
following prior chemotherapy for advanced disease. The 
licensing is a little different in Europe than in the USA, 
stipulating one and two prior chemotherapy regimens for 
advanced disease, respectively. In either case, previous treat-
ment should include an anthracycline and a taxane in either 
the adjuvant or metastatic setting. Approval was based on 
the results of two large, randomized Phase III clinical trials – 
EMBRACE2 and the 301 Study (Table 1).21
Advanced breast cancer response to eribulin was initially 
studied in two single-arm Phase II studies. In the 201 Study,22 
patients were initially treated with eribulin on days 1, 8, 
and 15 of a 28-day cycle. Due to unacceptable hematologi-
cal toxicity, requiring dose delays and dose modifications, 
the regimen was adjusted to the now standard schedule of 
eribulin on days 1 and 8 of a 21-day cycle. The subsequent 
211 Study assessed efficacy of this modified schedule in 
291 breast cancer patients with heavily pretreated advanced 
disease.23 The objective response rate (ORR; complete + 
partial response) reported by independent review was 9.3%, 
the median progression-free survival (PFS) was 2.6 months 
(range: 0.03–13.1 months), and the median overall 
survival (OS) was 10.4 months (range: 0.6–19.9 months). 
The subsequent EMBRACE study was an international 
open-label Phase III trial of eribulin compared to treatment 
of physician’s choice in breast cancer patients pretreated 
with two to five prior chemotherapy regimens including an 
anthracycline and a taxane.2 A total of 762 patients were ran-
domized (2:1) to eribulin or treatment of physician’s choice 
(vinorelbine 25%, gemcitabine 19%, capecitabine 18%, and 
others 38%). The study reported a 2.5-month improvement 
in OS with eribulin (median OS 13.1 vs 10.6 months, hazard 
ratio [HR] =0.81, 95% confidence interval [CI]: 0.66–0.99; 
P=0.041). A small increase in PFS was reported for the 
eribulin group on independent review, but the HR was not 
statistically significant (median PFS 3.7 vs 2.2 months, 
HR =0.87, 95% CI: 0.71–1.05; P=0.137). The ORR by 
independent review was 12% vs 5% (P=0.002).
The 301 Study was an international open-label Phase III 
trial of eribulin compared to capecitabine in 1102 women with 
metastatic breast cancer who had received up to two lines of 
prior chemotherapy for advanced disease;21 20%, 52%, and 
27% of patients received study treatment as first-, second-, 
and third-line therapies, respectively. The study reported no 
significant difference between treatment arms for OS, PFS, 
or ORR. The median OS was 15.9 and 14.5 months for the 
eribulin and capecitabine groups, respectively (HR =0.88, 
95% CI: 0.77–1.00; P=0.056). The median PFS was 4.1 vs 
4.2 months (HR =1.08, 95% CI: 0.93–1.25; P=0.30), and the 
ORR was 11.0 vs 11.5% (P=0.85).
A pooled analysis of these two Phase III trials reported 
an overall OS benefit of 2.4 months with eribulin compared 
to that with control therapy (HR =0.85, 95% CI: 0.77–0.95; 
P=0.003) and an overall PFS benefit of 0.6 months (HR =0.90, 
95% CI: 0.81–0.997; P=0.046).24 All analyzed patient sub-
groups favored treatment with eribulin compared to control, 
with particular OS benefit observed in patients with Her2-
negative disease (HR =0.82, 95% CI: 0.72–0.93; P=0.002), 
Table 1 Clinical trials leading to the licensing of eribulin for locally advanced and metastatic breast cancer
Study Study design Eligibility criteria Number 
of patients
ORR (%) Median PFS Median OS
Cortes 
et al23
Single-arm Phase ii Prior anthracycline, 
taxane and capecitabine
291 9.3 2.6 months  
(0.03–13.1 months)
10.4 months  
(0.6–19.9 months) 
Cortes 
et al2
Open-label randomized 
Phase III, eribulin  
vs treatment of 
physicians choice
Two to five previous 
chemotherapy regimens 
including an anthracycline 
and a taxane
762 12 vs 5 3.7 vs 2.2 months, HR =0.87 
(95% Ci: 0.71–1.05), P=0.137
13.1 vs 10.6 months, HR =0.81 
(95% Ci: 0.66–0.99), P=0.041
Kaufman 
et al21
Open-label randomized 
Phase III, eribulin  
vs capecitabine
Up to two prior 
chemotherapy regimens 
for advanced disease
1,102 11.0 vs 11.5 4.1 vs 4.2 months, HR =1.08 
(95% Ci: 0.93–1.25), P=0.30
15.9 vs 14.5 months, HR =0.88 
(95% Ci: 0.77–1.00), P=0.056
Abbreviations: CI, confidence interval; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
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TNBC (HR =0.74, 95% CI: 0.60–0.92; P=0.006), and patients 
with .2 organs involved with disease (HR =0.77, 95% 
CI: 0.66–0.89; P,0.001).
It is interesting to speculate on why eribulin may improve 
OS with little gain in PFS. As previously discussed, eribulin 
has various antitumor effects, including reversal of EMT, 
vascular remodeling, and associated improvement in tumor 
hypoxia. These effects may alter the biology of the under-
lying disease and enhance tumor response to subsequent 
chemotherapy.15 Subsequent clinical studies have sought 
to develop the role of eribulin for the treatment of breast 
cancer, either in specific patient subgroups, earlier in the 
patient pathway, or in combination with other anticancer 
therapies (Table 2).
Studies have largely reported response to eribulin in 
female breast cancer patients; however, a small retrospec-
tive study suggests efficacy in male breast cancer patients 
too.25 Older patients are often excluded from clinical trials. 
A pooled analysis of 827 patients treated in either the 
EMBRACE trial or the preceding Phase II studies reported 
outcomes according to age.26 A total of 10% of patients 
included in these studies were aged $70 years. No significant 
differences were observed in ORR, PFS, or OS by age. Toxic-
ity was similar across all age groups, although the incidence 
of grade 3/4 fatigue and peripheral neuropathy was highest 
in patients aged $70 years. A current study is specifically 
addressing the question of toxicity and response to eribulin 
in older patients (.70 years) with advanced breast cancer 
(NCT02404506). Patients with brain metastases are also 
often excluded from clinical trials. There have been several 
case reports describing response to eribulin in breast cancer 
patients with brain metastases,27 and a small prospective 
study to assess eribulin response in this group of patients is 
currently open to recruitment (NCT02581839).
A single-arm Phase II study of eribulin as first-line 
therapy for 56 patients with locally advanced or metastatic 
Her2-negative breast cancer reported an ORR of 28.6% and 
a median PFS of 6.8 months (95% CI: 4.4–7.6 months).28 
A Phase III trial of eribulin compared to weekly paclitaxel as 
first- or second-line therapy for patients with locally recurrent 
or metastatic Her2-negative breast cancer is currently open 
to recruitment (NCT02037529).
A single-arm Phase II study of eribulin + trastuzumab 
as first-line therapy for 52 patients with advanced Her2-
positive breast cancer reported promising activity with 
an ORR of 71% and a median PFS of 11.6 months (95% 
CI: 11.6–13.9 months).29 With current standard of care for 
first-line Her2-positive advanced breast cancer patients 
now including pertuzumab, the results of an ongoing 
Phase II study of eribulin in combination with trastuzumab + 
pertuzumab (NCT01912963) will provide an indication of its 
utility earlier in the treatment pathway for these patients.
Eribulin clearly has supportive data for its use as a 
monotherapy in metastatic breast cancer, particularly in 
Her2-negative breast cancer and TNBC, and future studies 
will inform clinicians on its efficacy and safety in combina-
tion regimes.
The well-documented effects of eribulin on the tumor 
vasculature provided a rationale for studying the combination 
of eribulin with antiangiogenic therapy. A recently reported 
randomized Phase II study of 141 patients with metastatic 
breast cancer treated with eribulin ± ramucirumab, a recom-
binant human monoclonal antibody to VEGF receptor-2, 
reported no significant difference either in PFS, the primary 
endpoint (median PFS 4.4 vs 4.1 months, HR =0.83, 95% 
CI: 0.56–1.23; P=0.35), or in the secondary endpoints of 
OS and ORR.30 A study of eribulin in combination with 
bevacizumab for Her2-negative metastatic breast cancer is 
currently recruiting (NCT02175446).
A randomized Phase II study of eribulin + gemcitabine 
compared to paclitaxel + gemcitabine as first-line therapy for 
patients with Her2-negative metastatic breast cancer is ongo-
ing (NCT02263495). A study of eribulin in combination with 
the humanized antibody to programmed cell death-1 (PD-1) 
Table 2 Postlicensing studies of eribulin in patients with advanced breast cancer
Study Study design Study treatment Eligibility criteria Number 
of patients
ORR (%) Median PFS 
(months)
Median OS 
(months)
Mcintyre 
et al28
Single-arm Phase ii Eribulin First-line therapy, Her2-negative 56 28.6 6.8 NR
wilks  
et al29
Single-arm Phase ii Eribulin + trastuzumab First-line therapy, Her2-positive 52 71 11.6 NR
Yardley 
et al30
Randomized Phase II Eribulin ± ramucirumab Two to four previous chemotherapy 
regimens including an anthracycline 
and a taxane
141 21 vs 28 4.4 vs 4.1 13.5 vs 11.5
Abbreviations: NR, not reported; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
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receptor, pembrolizumab, for patients with metastatic TNBC 
is currently open to recruitment (NCT02513472). Other 
interesting combination studies currently open to recruitment 
in metastatic TNBC include eribulin + the mammalian target 
of rapamycin (mTOR) inhibitor everolimus (NCT02120469) 
and eribulin + PQR309, a pan phosphoinositide-3-kinase 
(PI3K) and mTOR inhibitor (NCT02723877).
Eribulin in early breast cancer
The ORR reported by studies of eribulin in pretreated patients 
with metastatic breast cancer is limited; however, the reduced 
peripheral neuropathy associated with eribulin treatment 
compared to other MTAs means that it is appealing as a 
potential option in the adjuvant and neoadjuvant settings 
(Table 3). A randomized (2:1) Phase II study of eribulin or 
weekly paclitaxel followed by doxorubicin and cyclophos-
phamide in 49 women with locally advanced nonmetastatic 
Her2-negative breast cancer reported pathological complete 
response (pCR) in 5/30 (17%) and 5/19 (26%) patients, 
respectively,31 with similar rates of breast-conserving sur-
gery following either regime (28% vs 33%); reported levels 
of neurotoxicity were minimal and similar in both arms. 
Preliminary reports from a randomized (2:1) Phase II study 
of eribulin + cyclophosphamide vs docetaxel + cyclophos-
phamide in 66 patients with locally advanced Her2-negative 
breast cancer reported pCR in 5/37 (14%) and 2/18 (11%) 
patients, respectively;32 the incidence of peripheral neuropa-
thy with docetaxel was worse than with eribulin (45% vs 
30% of patients). A Phase II study of neoadjuvant eribulin + 
carboplatin in 30 women with TNBC reported pCR in 13/30 
(43%) patients.33 A Phase I/II study of neoadjuvant eribulin + 
carboplatin + trastuzumab for early Her2-positive breast 
cancer reported pCR in 2/12 (17%) patients but reported 
unacceptable hematological toxicity with grade 3/4 neutro-
penia in 9/12 patients, anemia requiring blood transfusion 
in 8/12 patients, and thrombocytopenia requiring platelet 
transfusion in 2/12 patients.34
It is unlikely with current evidence that eribulin in the 
neoadjuvant setting will replace current standard regimes. 
However, it may have a role as an adjuvant therapy in 
patients who do not achieve pCR with standard regimes, and 
an ongoing Phase II trial is evaluating the use of eribulin in 
these patients (NCT01401959). In addition, a recent Phase II 
study assessed eribulin + capecitabine as adjuvant therapy 
in postmenopausal women with early-stage, Her2-negative, 
estrogen receptor (ER)-positive breast cancer;35 this combina-
tion was considered feasible and suitable for further study in 
a larger randomized trial.
Safety and tolerability
Eribulin has an acceptable side effect profile (Table 4). The 
most common adverse events reported in the EMBRACE2 
Table 3 Clinical trials of neoadjuvant eribulin in early breast cancer
Study Study design Study treatment Eligibility criteria Number 
of patients
pCR (%)
Abraham  
et al31
Randomized (2:1) Phase II Eribulin vs weekly paclitaxel, then 
doxorubicin + cyclophosphamide 
Her2-negative 49 17 vs 26
Yardley  
et al32
Randomized (2:1) Phase II Eribulin + cyclophosphamide vs 
docetaxel + cyclophosphamide
Her2-negative 66 14 vs 11
Kaklamani 
et al33
Single-arm Phase ii Eribulin + carboplatin TNBC 30 43
Schwartzberg 
et al34
Phase i/ii Eribulin + carboplatin + trastuzumab Her2-positive 12 17
Abbreviations: pCR, pathological complete response; TNBC, triple-negative breast cancer.
Table 4 Pooled incidence of common adverse events reported 
by patients treated with eribulin (n=1,047) in the two randomized 
Phase III trials of eribulin for advanced breast cancer (EMBRACE2 
and 301 Study21)
Adverse 
event
All grades Grade 3 Grade 4
Number 
of patients
% Number 
of patients
% Number 
of patients
%
Neutropenia 555 53 240 23 236 23
Leukopenia 287 27 132 13 20 2
Anemia 198 19 20 2 1 ,1
Fatigue/asthenia 444 42 74 7 4 ,1
Alopecia 412 39
Peripheral 
neuropathy
323 31 74 7 5 ,1
Nausea 295 28 7 1 0 0
Diarrhea 170 16 6 1 0 0
Pyrexia 175 17 3 ,1 0 0
Headache 166 16 6 1 0 0
Anorexia 166 16 5 ,1 0 0
vomiting 156 15 5 ,1 2 ,1
Back pain 135 13 11 1 1 ,1
Dyspnea 135 13 28 3 2 ,1
Bone pain 110 11 19 2 1 ,1
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and 301 Study21 were hematological toxicities, including 
grade 3/4 neutropenia in 45% of patients; despite this, the 
reported incidence of febrile neutropenia across both studies 
was low (3%). Other common adverse events included alo-
pecia, nausea, and fatigue. Peripheral neuropathy (all grades) 
was reported in 31% of patients, with grade 3/4 peripheral 
neuropathy in 8% of cases.
A health-related quality of life analysis of patients treated 
within the 301 Study reported similar treatment effects on 
patient functioning irrespective of treatment arm. As might 
be expected from their side effect profiles, patients treated 
with capecitabine reported worse gastrointestinal symptoms 
(diarrhea, nausea, and vomiting), while patients treated with 
eribulin reported worse systemic side effects, including hair 
loss, dry eyes, altered taste, and headaches.36
Three recent retrospective studies have reported multiin-
stitutional experience with eribulin in clinical practice.37–39 
Of these three studies, 504 patients with advanced breast 
cancer received eribulin. Treatment responses and adverse 
events were consistent with outcomes reported from the pro-
spective randomized Phase III trials. Toxicity data may have 
been incompletely reported by these retrospective studies, 
but the pooled incidence of the most common toxicities (all 
grades) was fatigue (59%), neutropenia (35%), and periph-
eral neuropathy (34%); grade 3/4 neuropathy was reported 
in 16/504 patients (3%). These studies underline the toler-
ability of eribulin therapy by patients and its comparable side 
effect profile with other chemotherapeutic agents used in the 
management of metastatic breast cancer.
Conclusion
Eribulin is a novel MTA, which is now well established as 
a treatment option for patients with advanced breast cancer 
who have previously received chemotherapy with an anthra-
cycline and a taxane. Preclinical studies demonstrate that 
eribulin has wider antitumor effects beyond that of a simple 
antimitotic agent, including tumor vascular remodeling and 
reversal of EMT. The clinically significant improvements in 
OS, despite modest differences in PFS reported by the large 
randomized Phase III clinical trials of eribulin in advanced 
breast cancer patients, suggest that these off-target effects 
play an important contribution to its therapeutic activity. 
Ongoing and future studies will further define the role for 
eribulin in the treatment of both early and advanced breast 
cancer, as a monotherapy and in combination with other 
anticancer agents.
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